Difficulty: Medium
Average Score: 81%
Practice
What should patients with chronic myelocytic leukemia be told about abdominal discomfort due to splenic enlargement?
Correct answer
C
Rationale
In chronic myelocytic leukemia, splenic enlargement is a common occurrence due to infiltration of leukemic cells in the spleen. Therefore, patients experiencing abdominal discomfort due to splenic enlargement need to be informed about the appropriate management. Option C, which states that analgesics without aspirin are recommended to relieve discomfort, is the correct answer.
This is because aspirin can exacerbate bleeding tendencies in patients with leukemia due to its antiplatelet effects. Choosing analgesics without aspirin helps in managing the discomfort without increasing the risk of bleeding complications.
Option A is incorrect because splenic enlargement in chronic myelocytic leukemia is not a normal part of the aging process; it is a pathological manifestation of the disease. Option B is incorrect as splenic enlargement in this context is not a direct side effect of the therapeutic regimen but rather a consequence of the disease process itself. Option D is incorrect as not all analgesics are safe for patients with leukemia, especially those that can worsen bleeding tendencies.
From an educational standpoint, it is crucial for healthcare providers to educate patients with chronic myelocytic leukemia about the potential complications of splenic enlargement and the appropriate management strategies to ensure optimal care and quality of life for the patients. Understanding these nuances is vital in providing safe and effective care for patients with hematologic conditions.
This is because aspirin can exacerbate bleeding tendencies in patients with leukemia due to its antiplatelet effects. Choosing analgesics without aspirin helps in managing the discomfort without increasing the risk of bleeding complications.
Option A is incorrect because splenic enlargement in chronic myelocytic leukemia is not a normal part of the aging process; it is a pathological manifestation of the disease. Option B is incorrect as splenic enlargement in this context is not a direct side effect of the therapeutic regimen but rather a consequence of the disease process itself. Option D is incorrect as not all analgesics are safe for patients with leukemia, especially those that can worsen bleeding tendencies.
From an educational standpoint, it is crucial for healthcare providers to educate patients with chronic myelocytic leukemia about the potential complications of splenic enlargement and the appropriate management strategies to ensure optimal care and quality of life for the patients. Understanding these nuances is vital in providing safe and effective care for patients with hematologic conditions.